Drug candidates

Traumakine, interferon-beta (inducer of CD 73 expression), acute use of interferon, to prevent vascular leakage in acute lung injury (ALI) and other traumatic conditions.

FP-1201

Acute lung injury (ALI)

<0.5 million (orphan)

Sepsis/trauma MOF

1-2 millions

Surgical operations

5-10 millions

Farbetic (AOC3 inhibitor), vitamin B1 analog(s) to prevent incipient vasculopathies, e.g. in metabolic syndrome patients.

FP-1101/1102

Metabolic syndrome

> 80 millions

Diabetes

≈ 50 millions

Clevegen (a fully humanized antibody against Clever-1), to prevent inflammation and cancer spread.

FP-1302

Metastasis

> 25 millions

Inflammations

> 40 millions